Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients

Haematologica

Volumn 92, Issue 6, 2007, Pages 819-825

  Juvonen, Eeva ^a   Aalto, Sanna ^b   Tarkkanen, Jussi ^b   Volin, Liisa ^a   Hedman, Klaus ^b   Ruutu, Tapani ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

EBV; Predictive factors; PTLD; Reactivation; Viremia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BLOOD SAMPLING; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; GRAFT RECIPIENT; HLA MATCHING; HUMAN; INFECTION RISK; LIVING DONOR; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SIBLING; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT OUTCOME; VIREMIA; VIRUS REACTIVATION; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; BLOOD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; ISOLATION AND PURIFICATION; PHYSIOLOGY; RISK FACTOR; VIRUS ACTIVATION; VIRUS INFECTION;

DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY TESTING; HUMANS; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 34347259939     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.10751     Document Type: Article

References (30)

1. Munz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, Kurilla MG, et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 2000;191:1649-60.
2. Callan MF. The immune response to Epstein-Barr virus. Microbes Infect 2004;6:937-45.
3. Faye A, Vilmer E. Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options. Paediatr Drugs 2005;7:55-65.
4. Sundin M, Le Blanc K, Ringden O, Barkholt L, Omazic B, Lergin C, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006; 91:1059-67.
5. Juvonen E, Aalto SM, Tarkkanen J, Volin L, Mattila PS, Knuutila S, et al. High incidence of PTLD after non-T-cefl-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003; 32:97-102.
6. Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NK, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999;23:251-8.
7. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999;94:2208-16.
8. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003; 31:145-55.
9. Kruger WH, Schuler F, Lotze C, Schwesinger G, Mentel R, Busemann C, et al. Epstein-Barr virus reactivation after allogeneic stem cell transplantation without lymph node enlargement. Ann Hematol 2005;84:477-8.
10. Cohen J, Gandhi M, Naik P, Cubitt D, Rao K, Thaker U, et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005;129:229-39
11. Snyder MJ, Stenzel TT, Buckley PJ, Lagoo AS, Rizzieri DA, Gasparetto C, et al. Posttransplant lymphoproliferative disorder following non-myeloablative allogeneic stem cell transplantation. Am J Surg Pathol 2004;28:794-800.
12. Brunstein CG, Weisdorf DJ, Defor T, Barker JN, Tolar J, van Burik JA, et al. Marked increased risk of Epstein-barr virus-related complications with the addition of anti-thymocyte globulin to a non-myeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006;108:2874-80.
13. Barker JN, Martin PL, Coad JE, DeFor T, Trigg ME, Kurtzberg J, et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 2001;7:395-9.
14. Peres E, Savasan S, Klein J, Abidi M, Dansey R, Abella E. High fatality rate of Epstein-Barr virus-associated lymphoproliferative disorder occurring after bone marrow transplantation with rabbit antithymocyte globulin conditioning regimens. J Clin Microbiol 2005;43:3540-3.
15. Park S, Noguera ME, Briere J, Feuillard J, Cayuela JM, Sigaux F, et al. Successful rituximab treatment of an EBV-related lymphoproliferative disease arising after autologous transplantation for angioimmunoblastic T-cell lymphoma. Hematol J 2002-3:317-20.
16. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, et al. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999;68:1517-25.
17. Svoboda J, Kotloff R, Tsai DE. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int 2006;19:259-69.
18. Gottschalk S, Heslop HE, Roon CM. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 2002; 84:175-201.
19. Greenfield HM, Gharib MI, Turner AJ, Guiver M, Carr T, Will AM, et al. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention? Pediatr Blood Cancer 2006;47:200-5.
20. Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004;103:3979-81.
21. Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006;37:539-46.
22. Van Esser JW, Niesters HG, Van Der Holt B, Meijer E, Osterhaus AD, Gratama JW, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364-9.
23. Ruutu T, Volin L, Parkkali T, Juvonen E, Elonen E. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000;96:2391-8.
24. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-A matched sibling donors. Transplantation 1974;18:295-304.
25. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE, et al. Bone-marrow transplantation (second of two parts). N Engl J Med 1975;292:895-902.
26. Aalto SM, Juvonen E, Tarkkanen J, Volin L, Ruutu T, Mattila PS, et al. Lymphoproliferative disease after allogeneic stem cell transplantation - pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum. J Clin Virol 2003;28:275-83.
27. Annels NE, Kalpoe JS, Bredius RG, Claas EC, Kroes AC, Hislop AD, et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006; 42:1743-8.
28. Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E, et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005;128:224-33.
29. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001;98:972-8.
30. Torre-Cisneros J, Roman J, Torres A, Herrera C, Caston JJ, Rivero A, et al. Control of Epstein-Barr virus load and lymphoproliferative disease by maintenance of CD8+ T lymphocytes in the T lymphocyte-depleted graft after bone marrow transplantation. J Infect Dis 2004;190:1596-9.